gdc
Melanoma

Drugs for Melanoma

Here are the financial support services available to patients receiving treatment for Melanoma.

Braftovi (encorafenib) + Mektovi (binimetinib)

Drug company: Array BioPharma
866-277-2927

Braftovi plus Mektovi are 2 kinase inhibitors that are used together for the treatment of patients with unresectable (cannot be removed by surgery) or with metastatic melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

Array BioPharma, through its ArrayActs program, offers 2 financial assistance programs for patients who have been prescribed Braftovi plus Mektovi:

Array Co-Pay Savings Program

Patients who have private insurance will pay as little as $0 per month for their prescription of Braftovi plus Mektovi, with an annual maximum of $25,000.

Array Patient Assistance Program

This program offers financial assistance for Braftovi plus Mektovi to eligible patients with commercial or government insurance who are uninsured or underinsured.

Cotellic (cobimetinib)

Drug company: Genentech
866-422-2377

Cotellic is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with Zelboraf.

Genentech offers 2 financial assistance programs for patients using Cotellic:

Genentech BioOncology Co-pay Card

The program ensures a $5 copay, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Cotellic free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Cotellic is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Imlygic (talimogene laherparepvec)

Drug company: Amgen
888-427-7478

Imlygic is a genetically modified oncolytic viral therapy used for the treatment of patients with unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma.

Amgen offers 2 financial assistance programs for patients using Imlygic:

Imlygic First Step Program

For privately insured patients whose insurance covers Imlygic, this program ensures a copay of $0 for the first dose and $5 for each dose thereafter, with a maximum benefit of $10,000 per patient, per calendar year.

Amgen Safety Net Foundation

Qualifying, uninsured patients can receive Imlygic for free through Amgen’s nonprofit program.

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Keytruda is a PD-1–blocking antibody used for the treatment of patients with unresectable or metastatic melanoma.

The Merck Access Program offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Privately insured patients will pay the first $25 of their copay per infusion. The maximum benefit per calendar year is $25,000 for patients with an annual income level up to 700% of the federal poverty level, and $10,000 for patients with an annual income above 700% of the federal poverty level.

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive free Keytruda. Eligible patients must have an annual household income of $60,700 or less for individuals, $82,300 or less for couples, or $125,500 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines, may request that an exception be made, provided that their household income is not above a set limit.

Mekinist (trametinib)

Drug company: Novartis
800-245-5356

Mekinist is a kinase inhibitor used, as a single agent or in combination with Tafinlar, for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E or V600K mutation, as detected by an FDA-approved test. Mekinist, in combination with Tafinlar, is also used for adjuvant treatment of patients with melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), after complete resection (tumor removal).

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Mekinist:

Novartis Oncology Universal Co-pay Card

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Mekinist for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Mekinist for free for 1 year, or until prescription drug coverage becomes available to them.

Opdivo (nivolumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Opdivo is a PD-1 inhibitor used for the treatment of patients with unresectable or metastatic melanoma, as a single agent or in combination with Yervoy.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Opdivo. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per drug (or $50,000 annually for 2 BMS drugs administered in combination).

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $36,420 for an individual or $49,380 for a family of 2.

Tafinlar (dabrafenib)

Drug company: Novartis
800-245-5356

Tafinlar is a kinase inhibitor used, as a single agent or in combination with Mekinist, for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E mutation, as detected by an FDA-approved test. Tafinlar, in combination with Mekinist, is also used for adjuvant treatment of patients with melanoma and a BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), after complete resection (tumor removal).

Novartis’ Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tafinlar:

Novartis Oncology Universal Co-pay Card

Through this program, patients with private insurance will be responsible for up to the first $25 in copay and coinsurance. The program pays the remaining balance until a yearly maximum of $15,000 is met.

Novartis Patient Assistance Foundation

Patients who are experiencing financial hardship and have limited or no public or private prescription coverage may be able to receive Tafinlar for free through the Novartis Patient Assistance Foundation. To be eligible, the patient must be a US citizen, and have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household. Eligible patients will receive Tafinlar for free for 1 year, or until prescription drug coverage becomes available to them.

Yervoy (ipilimumab)

Drug company: Bristol-Myers Squibb
800-861-0048

Yervoy is a human cytotoxic T-lymphocyte antigen 4–blocking antibody used for the treatment of patients with unresectable or metastatic melanoma. Yervoy is also used as an adjuvant treatment for cutaneous melanoma.

Bristol-Myers Squibb Access Support offers 2 financial assistance programs for patients using Yervoy:

BMS Oncology Co-Pay Assistance Program

The program provides financial assistance with the out-of-pocket deductibles, copay, or coinsurance costs for eligible, privately insured patients who have been prescribed Yervoy. Patients pay a $25 copay, and BMS covers the remaining amount, up to $25,000 annually per drug (or $50,000 annually for 2 BMS drugs administered in combination).

Bristol-Myers Squibb Patient Assistance Foundation

Patients who don’t have public or private insurance that helps to pay for Yervoy may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $36,420 for an individual or $49,380 for a family of 2.

Zelboraf (vemurafenib)

Drug company: Genentech
866-422-2377

Zelboraf is a kinase inhibitor used for the treatment of patients with unresectable or metastatic melanoma and BRAF V600E mutation.

Genentech offers 2 financial assistance programs for patients using Zelboraf:

Genentech BioOncology Co-pay Card

The program ensures a $5 copay, with up to $25,000 provided annually, and has no income requirements for participation.

Genentech Patient Foundation

This foundation provides Zelboraf free of charge to uninsured or underinsured patients whose annual household income is less than $150,000. Zelboraf is also provided free of charge for patients who have an annual household income of up to $75,000 for 1 person; $100,000 for 2 people; $125,000 for 3 people; $150,000 for 4 people; and up to $25,000 more for each additional person in the household.

Table. Drugs Prescribed for Melanoma

  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services



    Drug name (generic name)
  • Mekinist (trametinib)
  • Drug company
  • Novartis
  • Indication
  • Unresectable or metastatic melanoma with BRAF V600E or V600K mutation, as a single agent or in combination with Tafinlar

    Adjuvant treatment, in combination with Tafinlar, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection

  • Patient support services
  • Novartis Oncology Universal Co-pay Card
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254


    Drug name (generic name)
  • Tafinlar (dabrafenib)
  • Drug company
  • Novartis
  • Indication
  • Unresectable or metastatic melanoma
    with BRAF V600E mutation, as a single agent or in combination with Mekinist

    Adjuvant treatment, in combination with Mekinist, for patients with melanoma and a BRAF V600E or V600K mutation, and involvement of lymph node(s), after complete resection

  • Patient support services
  • Novartis Oncology Universal Co-pay Card
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254



Last modified: February 11, 2019

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country